Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (49)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morrish, P. K.
Right arrow Articles by Brooks, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrish, P. K.
Right arrow Articles by Brooks, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 119, No. 6, 2097-2103, 1996
© 1996 Guarantors of Brain

research-article

Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease

P. K. Morrish1,, G. V. Sawle3 and D. J. Brooks1,2

1MRC Cyclotron Unit, Hammersmith Hospital London 2Institute of Neurology London 3Division of Clinical Neurology, Queens Medical Centre Nottingham, UK

Correspondence to: Correspondence to: Dr P. K. Morrish, MRC Cyclotron Unit, Hammersmith Hospital, DuCane Road, London, W12 OHS, UK

We have investigated regional changes in dopamine metabolism within the basal ganglia with clinical progression of idiopathic Parkinson's disease, using coregistration of [18F]dopa-PET and MRI images and comparing six normal subjects with 15 Parkinson's disease patients in a cross-sectional study. We have demonstrated that [18F]dopa metabolism in the dorsal putamen is reduced to almost 50% of normal both caudally and rostrally early in the disease whilst the ventral putamen is not significantly affected. With progression of symptoms there is loss of dopa metabolism from the ventral putamen, the ventrocaudal putamen in advance of the ventrorostral putamen. Throughout the disease the ventrorostral putamen is relatively preserved; even in the most advanced group [18F]dopa uptake is reduced here by only 30%. We conclude that the progression of Parkinson's disease is associated with a focal process affecting only the dorsal putamen in its early (and preclinical) phase then affecting the ventral putamen with increasing disease severity.

Parkinson's disease; [18F]dopa; progression; intrastriatal

Received March 27, 1996. Revised June 6, 1996. Accepted July 15, 1996.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
P. Jokinen, H. Helenius, E. Rauhala, A. Bruck, O. Eskola, and J. O. Rinne
Simple Ratio Analysis of 18F-Fluorodopa Uptake in Striatal Subregions Separates Patients with Early Parkinson Disease from Healthy Controls
J. Nucl. Med., June 1, 2009; 50(6): 893 - 899.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
X.-B. Pan, T. G. Wright, F. J. Leong, R. A. McLaughlin, J. M. Declerck, and D. H.S. Silverman
Improving Influx Constant and Ratio Estimation in FDOPA Brain PET Analysis for Parkinson's Disease
J. Nucl. Med., October 1, 2005; 46(10): 1737 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 Neurorehabil Neural RepairHome page
W. -L. Kuan and R. A. Barker
New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants
Neurorehabil Neural Repair, September 1, 2005; 19(3): 155 - 181.
[Abstract] [PDF]

Home page
 BrainHome page
A. W. Michell, S. J. G. Lewis, T. Foltynie, and R. A. Barker
Biomarkers and Parkinson's disease
Brain, August 1, 2004; 127(8): 1693 - 1705.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Biraben, F. Semah, M. -J. Ribeiro, G. Douaud, P. Remy, and A. Depaulis
PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy
Neurology, July 13, 2004; 63(1): 73 - 77.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. L. Whone, D. L. Bailey, P. Remy, N. Pavese, and D. J. Brooks
A Technique for Standardized Central Analysis of 6-18F-Fluoro-L-DOPA PET Data from a Multicenter Study
J. Nucl. Med., July 1, 2004; 45(7): 1135 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
S. McGowan, A. D. Lawrence, T. Sales, D. Quested, and P. Grasby
Presynaptic Dopaminergic Dysfunction in Schizophrenia: A Positron Emission Tomographic [18F]Fluorodopa Study
Arch Gen Psychiatry, February 1, 2004; 61(2): 134 - 142.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. J. G. Lewis, A. Dove, T. W. Robbins, R. A. Barker, and A. M. Owen
Cognitive Impairments in Early Parkinson's Disease Are Accompanied by Reductions in Activity in Frontostriatal Neural Circuitry
J. Neurosci., July 16, 2003; 23(15): 6351 - 6356.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
I. K. Goerendt, C. Messa, A. D. Lawrence, P. M. Grasby, P. Piccini, and D. J. Brooks
Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study
Brain, February 1, 2003; 126(2): 312 - 325.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
V. Dhawan, Y. Ma, V. Pillai, P. Spetsieris, T. Chaly, A. Belakhlef, C. Margouleff, and D. Eidelberg
Comparative Analysis of Striatal FDOPA Uptake in Parkinson's Disease: Ratio Method Versus Graphical Approach
J. Nucl. Med., October 1, 2002; 43(10): 1324 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
L. Shihabuddin, M. S. Buchsbaum, E. A. Hazlett, J. Silverman, A. New, A. M. Brickman, V. Mitropoulou, M. Nunn, M. B. Fleischman, C. Tang, et al.
Striatal Size and Relative Glucose Metabolic Rate in Schizotypal Personality Disorder and Schizophrenia
Arch Gen Psychiatry, September 1, 2001; 58(9): 877 - 884.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. T. M. Hu, S. J. White, A. H. Herlihy, K. R. Chaudhuri, J. V. Hajnal, and D. J. Brooks
A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease
Neurology, May 8, 2001; 56(9): 1195 - 1200.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K.-Y. Tzen, C.-S. Lu, T.-C. Yen, S.-P. Wey, and G. Ting
Differential Diagnosis of Parkinson's Disease and Vascular Parkinsonism by 99mTc-TRODAT-1
J. Nucl. Med., March 1, 2001; 42(3): 408 - 413.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
J. Schwarz, R. Linke, M. Kerner, P. D. Mozley, C. Trenkwalder, T. Gasser, and K. Tatsch
Striatal Dopamine Transporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed Tomography in Patients With Early Parkinson's Disease: Implications for a Preclinical Diagnosis
Arch Neurol, February 1, 2000; 57(2): 205 - 208.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
K Ito, P K Morrish, J S Rakshi, T Uema, J Ashburner, D L Bailey, K J Friston, and D J Brooks
Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 754 - 758.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P K Morrish, J S Rakshi, D L Bailey, G V Sawle, and D J Brooks
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET
J. Neurol. Neurosurg. Psychiatry, March 1, 1998; 64(3): 314 - 319.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.